Published in Clin Exp Immunol on November 01, 1978
Complement activation in Staphylococcus aureus bacteraemia. Clin Exp Immunol (1980) 0.75
"Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin. J Immunol (1966) 9.65
Precise standardization of reagents for complement fixation. Am J Trop Med Hyg (1963) 6.54
Rheumatoid factor, complement, and conglutinin aberrations in patients with subacute bacterial endocarditis. J Clin Invest (1962) 3.96
Significance of protein a production by staphylococci. Infect Immun (1970) 3.60
Opsonic, agglutinating, and complement-fixing antibodies in patients with subacute bacterial endocarditis. J Lab Clin Med (1968) 3.20
Infective endocarditis: a review of 125 cases from the University of Washington Hospitals, 1963-72. Medicine (Baltimore) (1977) 3.05
Relation of mucoid growth of Staphylococcus aureus to clumping factor reaction, morphology in serum-soft agar, and virulence. J Bacteriol (1968) 3.01
The immune complex glomerulonephritis of bacterial endocarditis. Medicine (Baltimore) (1972) 2.82
Infective endocarditis at the Presbyterian Hospital in New York City from 1938-1967. Am J Med (1971) 2.66
Protein A from Staphylococcus aureus. IX. Complement-fixing activity of protein A-IgG complexes. J Immunol (1969) 2.28
Musculoskeletal manifestations of bacterial endocarditis. Ann Intern Med (1977) 2.04
Teichoic acid antibodies in staphylococcal and nonstaphylococcal endocarditis. Ann Intern Med (1972) 2.03
Circulating immune complexes in infective endocarditis. N Engl J Med (1976) 2.02
Rheumatoid factors in subacute bacterial endocarditis--bacterium, duration of disease or genetic predisposition? Ann Intern Med (1968) 2.00
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
Serum complement component levels in human glomerulonephritis. Ann Intern Med (1971) 1.70
Diffuse glomerulonephritis associated with infected ventriculoatrial shunt. N Engl J Med (1968) 1.67
Non-suppurative lesions in staphylococcal septicaemia. J Pathol Bacteriol (1961) 1.65
A LONG-TERM VIEW OF BACTERIAL ENDOCARDITIS. 337 CASES 1924 TO 1963. Ann Intern Med (1965) 1.60
Use of bovine conglutinin for the assay of immune complexes. J Immunol (1977) 1.56
Thrombocytopenia and symmetrical peripheral gangrene associated with staphylococcal and streptococcal bacteremia. Ann Intern Med (1968) 1.46
Acute diffuse glomerulonephritis in acute staphylococcal endocarditis. Ann Intern Med (1969) 1.45
C3 proactivator (C3PA) as an acute phase reactant. Clin Exp Immunol (1974) 1.35
Speculations on the immunology of staphylococcal infections. Ann N Y Acad Sci (1965) 1.35
Activation and inhibition of IgG mediated complement fixation by staphylococcal protein A. Clin Exp Immunol (1970) 1.27
Pleural fluid complement in systemic lupus erythematosus and rheumatoid arthritis. Ann Intern Med (1972) 1.21
Blood coagulation and the inflammatory response. Semin Hematol (1977) 1.04
Glomerulonephritis due to Staphylococcus aureus antigen. Am J Clin Pathol (1976) 0.95
Vascular disease in infective endocarditis. Report of immune-mediated events in skin and brain. Arch Intern Med (1978) 0.88
Correlations between serum factor B and C3b inactivator levels in normal subjects and in patients with infections, nephrosis and hypocomplementaemic glomerulonephritis. Clin Exp Immunol (1977) 0.84
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest (1995) 7.68
Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry. Infect Immun (1993) 5.63
Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest (1997) 4.51
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Coccidioidomycosis: a reemerging infectious disease. Emerg Infect Dis (1996) 2.35
Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 2.24
Invasive Salmonella dublin infections associated with drinking raw milk. West J Med (1983) 2.19
Plasmid-mediated virulence in Salmonella dublin demonstrated by use of a Tn5-oriT construct. Infect Immun (1985) 2.10
Pseudomonas aeruginosa epidemic traced to delivery-room resuscitators. N Engl J Med (1967) 2.05
Natural history of oral Salmonella dublin infection in BALB/c mice: effect of an 80-kilobase-pair plasmid on virulence. J Infect Dis (1987) 2.05
When does rheumatoid arthritis begin and why do we need to know? Arthritis Rheum (2000) 2.05
The Salmonella typhimurium virulence plasmid complement resistance gene rck is homologous to a family of virulence-related outer membrane protein genes, including pagC and ail. J Bacteriol (1992) 1.89
Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest (1997) 1.86
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.85
Biology and clinical significance of virulence plasmids in Salmonella serovars. Clin Infect Dis (1995) 1.76
Palindromic rheumatism: part of or apart from the spectrum of rheumatoid arthritis. Am J Med (1992) 1.75
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum (1999) 1.75
Growth regulation of a Salmonella plasmid gene essential for virulence. J Bacteriol (1991) 1.74
Assessment of serum antibodies in patients with rapidly progressive sensorineural hearing loss and Menière's disease. Laryngoscope (1995) 1.74
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induces epithelial prostaglandin h synthase-2 expression and prostaglandin E2 and F2alpha production. J Clin Invest (1997) 1.68
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Carpal-tunnel syndrome. Results of a prospective trial of steroid injection and splinting. J Bone Joint Surg Am (1980) 1.66
Molecular analysis of the virulence locus of the Salmonella dublin plasmid pSDL2. Mol Microbiol (1991) 1.65
Inbred mouse strains differ in resistance to lethal Coccidioides immitis infection. Infect Immun (1983) 1.65
Corticosteroids and systemic lupus erythematosus pancreatitis: a case series. J Rheumatol (1998) 1.65
Correlation between the presence of sequences homologous to the vir region of Salmonella dublin plasmid pSDL2 and the virulence of twenty-two Salmonella serotypes in mice. Infect Immun (1990) 1.64
Physical and genetic mapping of the Salmonella dublin virulence plasmid pSDL2. Relationship to plasmids from other Salmonella strains. J Clin Invest (1988) 1.63
High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus (2011) 1.63
Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum (1992) 1.62
Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med (1986) 1.58
Pyarthrosis in patients with rheumatoid arthritis: a report of 13 cases and a review of the literature from the past 40 years. Am J Med (1990) 1.58
Deficient serum bactericidal activity against Escherichia coli in patients with cirrhosis of the liver. J Clin Invest (1979) 1.58
Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) (2001) 1.54
Human infection with Salmonella dublin. Medicine (Baltimore) (1991) 1.53
Genetic influences on endometriosis in an Australian twin sample. sueT@qimr.edu.au. Fertil Steril (1999) 1.51
Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension (2000) 1.50
Mechanism of resistance to complement-mediated killing of bacteria encoded by the Salmonella typhimurium virulence plasmid gene rck. J Clin Invest (1992) 1.50
Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens (1998) 1.48
The Salmonella spvB virulence gene encodes an enzyme that ADP-ribosylates actin and destabilizes the cytoskeleton of eukaryotic cells. Mol Microbiol (2001) 1.45
Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem (1984) 1.42
Intestinal epithelial cells as watchdogs for the natural immune system. Trends Microbiol (1995) 1.41
Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. Lupus (2001) 1.40
The crucial role of polymorphonuclear leukocytes in resistance to Salmonella dublin infections in genetically susceptible and resistant mice. Proc Natl Acad Sci U S A (1998) 1.40
Genetically resistant (Ityr) and susceptible (Itys) congenic mouse strains show similar cytokine responses following infection with Salmonella dublin. J Immunol (1996) 1.38
Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. J Biol Chem (1997) 1.38
Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.35
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Growth-phase regulation of plasmid virulence genes in Salmonella. Trends Microbiol (1995) 1.34
The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest (1999) 1.33
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Expression of Salmonella typhimurium rpoS and rpoS-dependent genes in the intracellular environment of eukaryotic cells. Infect Immun (1996) 1.31
Chromogranin A: immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. Life Sci (1983) 1.30
D-myo-Inositol 1,4,5,6-tetrakisphosphate produced in human intestinal epithelial cells in response to Salmonella invasion inhibits phosphoinositide 3-kinase signaling pathways. Proc Natl Acad Sci U S A (1997) 1.30
A plaque assay on agar for detection of gram-negative bacilli sensitive to complement. J Immunol (1972) 1.30
Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. Am J Med (1995) 1.29
Continuing medical education. Changing behavior and improving outcomes. Arthritis Rheum (1985) 1.28
Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum (2001) 1.26
Malassezia fungemia in neonates and adults: complication of hyperalimentation. Rev Infect Dis (1988) 1.25
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis (2003) 1.25
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis (2006) 1.24
Review: Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus (2009) 1.24
Specificity of the complement resistance and cell association phenotypes encoded by the outer membrane protein genes rck from Salmonella typhimurium and ail from Yersinia enterocolitica. Infect Immun (1994) 1.24
Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides (1998) 1.24
Rapidly destructive hip disease: clinical and imaging abnormalities. Radiology (1993) 1.23
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis (2007) 1.23
Influence of age and sex on plasma calcitonin in human beings. N Engl J Med (1980) 1.23
Development and validation of a noninvasive method to determine arterial pressure and vascular compliance. Am J Cardiol (1997) 1.22
Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondritis and Behçet's disease. Am J Med (1985) 1.22
Calcium and catecholamine interactions with adrenal chromogranins. Comparison of driving forces in binding and aggregation. J Biol Chem (1992) 1.22
Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul Pept (1983) 1.22
Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis (2005) 1.19
The rheumatic manifestations of leprosy (Hansen disease). Medicine (Baltimore) (1980) 1.19
Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum (1995) 1.18
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis (2011) 1.17
Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet (1998) 1.16
The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis. Clin Exp Immunol (2006) 1.15
Release of 51Cr-endotoxin from bacteria as an assay of serum bactericidal activity. J Immunol (1974) 1.15
Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med (1984) 1.14
Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) (1991) 1.14
Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation (1990) 1.14
Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. Mol Endocrinol (2000) 1.14
The arthritis of familial Mediterranean fever. Semin Arthritis Rheum (1992) 1.14
Molecular genetics of essential hypertension: recent results and emerging strategies. Curr Opin Nephrol Hypertens (2001) 1.13
Chronic pernio. A historical perspective of cold-induced vascular disease. Arch Intern Med (1986) 1.13
Distinctive biochemical features of Salmonella dublin isolated in California. J Clin Microbiol (1983) 1.13
Identification of a domain in Rck, a product of the Salmonella typhimurium virulence plasmid, required for both serum resistance and cell invasion. Infect Immun (1996) 1.12
Pyogenic arthritis of the shoulder in adults. J Bone Joint Surg Am (1980) 1.12
Chromogranin A. Storage and release in hypertension. Hypertension (1990) 1.12
Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem (1999) 1.12
The acute-phase response protects mice from D-galactosamine sensitization to endotoxin and tumor necrosis factor-alpha. Hepatology (1992) 1.12
Characterization of translation termination mutations in the spv operon of the Salmonella virulence plasmid pSDL2. J Bacteriol (1992) 1.12
An outbreak of Providencia stuartii urinary tract infections. Patients with condom catheters are a reservoir of the bacteria. JAMA (1981) 1.11
Predictors of hysterectomy: an Australian study. Am J Obstet Gynecol (1999) 1.11
Role of alphabeta and gammadelta T cells in the host response to Salmonella infection as demonstrated in T-cell-receptor-deficient mice of defined Ity genotypes. Infect Immun (1997) 1.10
Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion. J Clin Invest (2000) 1.10
Studies of the pathogenesis of interstitial cystitis, obstructive uropathy, and intestinal malabsorption in a patient with systemic lupus erythematosus. Am J Med (1981) 1.10